title: Interruption of natalizumab therapy for multiple sclerosis: what are the risks?
authors.forename: Robert T
authors.initials: RT
authors.lastname: Naismith
authors.forename: Dennis
authors.initials: D
authors.lastname: Bourdette
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D000069442:Natalizumab; D012008:Recurrence; D012307:Risk Factors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab